CAR T-Cell therapy in China
Till date, we have treated >2000 patients with our CAR T cells. Explore how we can help you get groundbreaking CAR T-Cell therapy in China.
Beijing Bioocus is a biotech company that focuses on manufacturing groundbreaking cellular therapies. Bioocus is not only a leading biotech company in China, but also a value-chain functional enterprise with a research center, GMP facility, CDMO and technology transfer platform. We are credited with some groundbreaking clinical trials for CAR T-Cell therapy in China.
Why choose China for CAR T-Cell therapy?
There has been significant progress made with respect to CAR T-Cell therapy in China. Chinese researchers and medical institutes have been actively developing and testing innovative CAR T-cell treatments for both solid tumors and hematological malignancies. China has been at the forefront of advancements in CAR T cell therapy, with multiple state-of-the-art clinical trials taking place there. Consequently, individuals seeking the latest advancements in CAR T cell therapy may consider China an attractive option.
Clinical Trials & Research
China is actively conducting clinical trials and research on CAR T cell therapy, demonstrating significant progress in advancing this innovative cancer treatment. As on date there are more than 700 ongoing clinical trials in China that is more than any other country on this planet. These efforts involve collaborations between academia, hospitals, and biotech companies, aiming to enhance patient outcomes and contribute to the global understanding of immunotherapy.
Cost And Availability
As we source CAR T directly from the manufacturer and multiple cells at our hospital's own lab, the overall cost of the therapy has come down considerably. The cost of CAR T-Cell therapy in China is considerably less than in nations such as the US, UK, Australia, Japan, Korea, and Singapore. The CAR T-Cell therapy cost in China is approximately $60,000 USD. China has a relatively abundant supply of CAR T.
With the recent regulatory license granted to more medical facilities in China, the wait times for CAR T cell therapy treatments may be reduced. Furthermore, CAR T cell therapy is often more cost-effective in China compared to other locations, such as the United States.
Experience & Expertise
China has gained substantial experience and expertise in CAR T cell therapy, showcasing a robust research landscape and significant clinical advancements. In China alone, hospital’s have done more than 6,000 CAR T therapies till date.
Chinese companies and research institutions are leading the development of novel CAR T cell therapies, contributing to the evolution of precision medicine and immunotherapy on a global scale.
Collaborations
In recent years, American businesses have begun collaborating with their Chinese counterparts to develop CAR T cell medicines. For ex. In 2015, WuXi AppTec, a Chinese contract research organization (CRO), and Juno Therapeutics, a US-based biopharmaceutical business, partnered strategically. Chinese biopharmaceutical company Cellular Biomedicine Group worked with US biopharmaceutical company Celgene, which is now a division of Bristol-Myers Squibb.
Johnson & Johnson-owned pharmaceutical company Janssen Biotech and Legend Biotech, a company with operations in both China and the US, entered into a global partnership and license agreement.
What do patients say about us?
“Dr. Zhang was very helpful finding the best doctor and hospital for my very complex treatment. I suffered with HIV and lymphoma together. After CAR T treatment, I am totally fine.”
Alxender Tarakov, Lymphoma Survival, Russia
